Viral Infection in Glioblastoma: Immunohistochemistry in Detection of Cytomegalovirus, Epstein-Barr and Herpes Simplex – 1 Virus

Introduction: Glioblastoma (GB) is the most aggressive glial tumor of the brain with a dismal prognosis. Studies conducted during the last two decades highlighted neurotropic viruses as a risk factors involved in development of glioblastoma. Authors present an immunohistological study conducted in a...

Full description

Saved in:
Bibliographic Details
Main Authors: Nenad Koruga, Tatjana Pekmezović, Ilijan Tomaš, Jasmina Rajc, Alen Rončević, Anamarija Soldo Koruga
Format: Article
Language:English
Published: Faculty of Medicine Osijek 2025-02-01
Series:Southeastern European Medical Journal
Subjects:
Online Access:https://seemedj.mefos.unios.hr/index.php/seemedj/article/view/338/211
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Glioblastoma (GB) is the most aggressive glial tumor of the brain with a dismal prognosis. Studies conducted during the last two decades highlighted neurotropic viruses as a risk factors involved in development of glioblastoma. Authors present an immunohistological study conducted in a single center on sixty-three archive paraffin-embedded samples of GB. Patients and methods: The tissues were tested using immunohistochemistry in a homogenous group of sixty-three glioblastoma paraffin-embedded tissues for the presence of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and herpes simplex virus type 1 (HSV-1). Results: Three species of herpes viruses were tested: HSV-1, Epstein-Barr virus (EBV) and Cytomegalovirus using the standard automatized immunohistochemistry. According to the IRS score, there were six samples of HSV-1 regarded as IRS 2 and five IRS 1 samples of the same virus. EBV and CMV were negative. Conclusion: The result of our study identified HSV-1 as the most prominent neurotropic virus among population surgically treated of GB. Further studies are necessary to confirm its possible oncomodulatory role.
ISSN:2459-9484